comparemela.com
2
3
4
5
6
7
8
Latest Breaking News On - Georgia cancer center - Page 1 : comparemela.com
CML: Asciminib Bests Standard TKIs as Frontline Therapy
Asciminib demonstrated efficacy vs standard-of-care frontline TKIs in newly diagnosed patients with CML.
New-york
United-states
Roswell-park
Georgia
Chicago
Illinois
American
Jorgee-cortes
Pankit-vachhani
Eunice-wang
University-of-alabama-at-birmingham
Drug-administration
ASCO 2024: Artificial Intelligence: Innovation and Potential for Diagnostic Imaging in Prostate Cancer
ASCO 2024, Prostate Cancer, Prostate-Specific Membrane Antigen Ligand Positron Emission Tomography (PSMA-PET), Diagnostic Imaging in Prostate Cancer, Artificial Intelligence in diagnostics, Innovation and Potential for Diagnostic Imaging in Prostate Cancer, PI-RADS guidelines.
United-states
Chicago
Illinois
Georgia
American
Zachary-klaassen
Stephaniea-harmon
Stephanie-harmon
Twitter
American-society-of-clinical-oncology
Molecular-imaging-program
Georgia-cancer-center
ASCO 2024: Artificial Intelligence and Deep Learning in Prostate Cancer Pathology
ASCO 2024, Prostate Cancer, Prostate Cancer Pathology, Artificial Intelligence and Deep Learning in Prostate Cancer Pathology, TMPRSS2:ERG fusion status.
Chicago
Illinois
United-states
Canada
Georgia
American
Liang-cheng
Zachary-klaassen
Williamb-schwartz
Laboratory-medicine
Twitter
Lancet-commission-on-prostate-cancer
ASCO 2024: Using Artificial Intelligence to Optimize Systemic Therapy for Prostate Cancer
ASCO 2024, Prostate Cancer, Artificial Intelligence to Optimize Systemic Therapy, Artificial Intelligence to Optimize Systemic Therapy for Prostate Cancer, Optimize Systemic Therapy for Prostate Cancer, artificial intelligence for prostate cancer, artificial intelligence for prostate cancer diagnostics.
Arizona
United-states
Georgia
Phoenix
Chicago
Illinois
American
Irbazb-riaz
Zachary-klaassen
Twitter
American-society-of-clinical-oncology
Georgia-cancer-center
ASCO 2024: A Phase 1 Study of JNJ-69086420 (JNJ-6420), an Actinium-225 (225Ac)-Labeled Antibody Targeting Human Kallikrein 2, for mCRPC
ASCO 2024, prostate cancer, metastatic castration-resistant prostate cancer (mCRPC), JNJ-69086420 (JNJ-6420), Actinium-225 (225Ac), Targeting Human Kallikrein 2, JNJ-6420 adverse events.
Memorial-sloan-kettering-cancer-center
New-york
United-states
Chicago
Illinois
Georgia
American
Michaelj-morris
Michael-morris
Zachary-klaassen
Twitter
American-society-of-clinical-oncology
vimarsana © 2020. All Rights Reserved.